TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that co-founder and CEO Adi Mor, PhD, will participate in Oppenheimer's Movers in Rare Disease Summit on Thursday, December 11, 2025, at the Sofitel Hotel in New York City. The invitation-only Rare Disease Summit will feature a day of panels, presentations and 1 ...

— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks— —New Clinical Data Provides Insights on Nebokitug’s Direct Macrophage-Mediated Mechanisms that Are Key to PSC Disease Progression— —All Three Presentations Have Been Designated as Posters of Distinction— TEL AVIV, Israel and WASHINGTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical sta ...

Core Insights - Chemomab Therapeutics Ltd. is a clinical stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet need [3] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference, with a prerecorded presentation available starting September 5, 2025 [1][2] Company Overview - Chemomab is developing nebokitug (CM-101), a first-in-class dual activity monoclonal antibody targeting the soluble protein CCL24, which plays a role in fibrosis and inflammation [3] - Nebokitug has shown disease-modifying potential and a favorable safety profile in clinical and preclinical studies, indicating its potential to treat severe fibro-inflammatory diseases [3] - The company has reported positive results from five clinical trials of nebokitug, particularly from the Phase 2 SPRING trial in primary sclerosing cholangitis (PSC) [3] - Chemomab is preparing for a potential Phase 3 trial in PSC, which will be a single pivotal trial with a clinical event primary endpoint, aiming for full regulatory approval [3] - Nebokitug has received Orphan Drug designation from the FDA and EMA, as well as Fast Track designation from the FDA for the treatment of PSC [3] - The program for treating systemic sclerosis with nebokitug has an open U.S. IND [3]

Core Insights - The SPRING trial data presented at Digestive Disease Week 2025 indicates that nebokitug is well-tolerated and shows significant improvements in multiple biomarkers related to fibrotic and inflammatory diseases, suggesting its potential as a first-in-class treatment for primary sclerosing cholangitis (PSC) [1][2][4] Group 1: Clinical Trial Results - The Phase 2 SPRING trial data demonstrated that nebokitug was safe and well-tolerated over a 48-week treatment period, with a safety profile comparable to placebo [2][3] - Nebokitug exhibited dose-dependent anti-inflammatory, anti-fibrotic, and anti-cholestatic effects, particularly in patients with moderate to severe disease, showing sustained improvements in biomarkers associated with disease progression [2][3] - In the open-label extension of the study, patients receiving nebokitug for up to 48 weeks showed continual improvement in fibrosis markers and stabilization of liver stiffness, especially at the 20 mg/kg dose [3] Group 2: Company Overview and Future Plans - Chemomab Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases, with nebokitug being a dual activity monoclonal antibody targeting CCL24 [8] - The company is preparing for a potential Phase 3 trial for nebokitug based on positive results from the Phase 2 SPRING trial, which has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC treatment [8] - The Phase 3 trial design aims for a single pivotal trial with a clinical event primary endpoint, providing a streamlined pathway to potential full regulatory approval [8]